News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
271,779 Results
Type
Article (14164)
Company Profile (108)
Press Release (257505)
Multimedia
Podcasts (61)
Webinars (13)
Section
Business (88387)
Career Advice (467)
Deals (15399)
Drug Delivery (69)
Drug Development (36730)
Employer Resources (50)
FDA (6364)
Job Trends (6237)
News (150845)
Policy (14142)
Tag
Academia (443)
Accelerated approval (6)
Adcomms (7)
Allergies (56)
Alliances (23378)
ALS (49)
Alzheimer's disease (454)
Antibody-drug conjugate (ADC) (77)
Approvals (6481)
Artificial intelligence (165)
Autoimmune disease (23)
Automation (6)
Bankruptcy (151)
Best Places to Work (4380)
BIOSECURE Act (9)
Biosimilars (91)
Biotechnology (40)
Bladder cancer (32)
Brain cancer (25)
Breast cancer (131)
Cancer (1073)
Cardiovascular disease (123)
Career advice (417)
Career pathing (13)
CAR-T (36)
CDC (6)
Cell therapy (125)
Cervical cancer (8)
Clinical research (31654)
Collaboration (555)
Compensation (267)
Complete response letters (29)
COVID-19 (776)
CRISPR (36)
C-suite (309)
Cystic fibrosis (52)
Data (1359)
Denatured (17)
Depression (29)
Diabetes (115)
Diagnostics (1361)
Digital health (6)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (90)
Drug pricing (102)
Drug shortages (12)
Duchenne muscular dystrophy (71)
Earnings (33084)
Editorial (16)
Employer branding (4)
Employer resources (45)
Events (38531)
Executive appointments (512)
FDA (7246)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (346)
Gene editing (57)
Generative AI (12)
Gene therapy (142)
GLP-1 (413)
Government (1384)
Grass and pollen (4)
Guidances (145)
Healthcare (3613)
HIV (7)
Huntington's disease (6)
IgA nephropathy (28)
Immunology and inflammation (59)
Immuno-oncology (4)
Indications (30)
Infectious disease (829)
Inflammatory bowel disease (68)
Inflation Reduction Act (7)
Influenza (19)
Intellectual property (88)
Interviews (60)
IPO (5914)
IRA (33)
Job creations (2057)
Job search strategy (375)
Kidney cancer (9)
Labor market (26)
Layoffs (204)
Leadership (8)
Legal (3456)
Liver cancer (21)
Longevity (6)
Lung cancer (158)
Lymphoma (89)
Machine learning (8)
Management (17)
Manufacturing (306)
MASH (57)
Medical device (1324)
Medtech (1327)
Mergers & acquisitions (9828)
Metabolic disorders (373)
Multiple sclerosis (39)
NASH (14)
Neurodegenerative disease (57)
Neuropsychiatric disorders (17)
Neuroscience (774)
NextGen: Class of 2025 (1593)
Non-profit (670)
Now hiring (15)
Obesity (195)
Opinion (136)
Ovarian cancer (33)
Pain (93)
Pancreatic cancer (39)
Parkinson's disease (64)
Partnered (9)
Patents (186)
Patient recruitment (85)
Peanut (12)
People (29525)
Pharmaceutical (64)
Pharmacy benefit managers (14)
Phase I (8234)
Phase II (13370)
Phase III (12046)
Pipeline (1063)
Policy (119)
Postmarket research (1402)
Preclinical (3309)
Press Release (25)
Prostate cancer (74)
Psychedelics (14)
Radiopharmaceuticals (125)
Rare diseases (269)
Real estate (2653)
Recruiting (18)
Regulatory (10637)
Reports (15)
Research institute (575)
Resumes & cover letters (55)
Rett syndrome (3)
RNA editing (5)
RSV (16)
Schizophrenia (57)
Series A (63)
Series B (34)
Service/supplier (3)
Sickle cell disease (40)
Special edition (10)
Spinal muscular atrophy (77)
Sponsored (8)
Startups (1642)
State (2)
Stomach cancer (3)
Supply chain (41)
Tariffs (66)
The Weekly (42)
Vaccines (212)
Venture capital (24)
Weight loss (126)
Women's health (12)
Worklife (4)
Date
Today (40)
Last 7 days (226)
Last 30 days (817)
Last 365 days (10889)
2025 (8874)
2024 (12545)
2023 (14291)
2022 (19613)
2021 (20110)
2020 (19087)
2019 (14956)
2018 (11777)
2017 (13919)
2016 (13155)
2015 (15499)
2014 (12443)
2013 (10628)
2012 (11422)
2011 (11942)
2010 (10916)
Location
Africa (318)
Alabama (17)
Alaska (1)
Arizona (69)
Arkansas (3)
Asia (20624)
Australia (2658)
California (2621)
Canada (1286)
China (430)
Colorado (111)
Connecticut (110)
Delaware (100)
Europe (40470)
Florida (511)
Georgia (71)
Hawaii (1)
Idaho (9)
Illinois (286)
India (30)
Indiana (202)
Iowa (1)
Japan (185)
Kansas (71)
Kentucky (17)
Louisiana (2)
Maine (2)
Maryland (372)
Massachusetts (2231)
Michigan (41)
Minnesota (140)
Mississippi (1)
Missouri (29)
Montana (8)
Nebraska (6)
Nevada (16)
New Hampshire (7)
New Jersey (1187)
New Mexico (7)
New York (762)
North Carolina (525)
North Dakota (2)
Northern California (1135)
Ohio (67)
Oklahoma (5)
Oregon (17)
Pennsylvania (629)
Puerto Rico (9)
Rhode Island (15)
South America (505)
South Carolina (7)
Southern California (1133)
Tennessee (46)
Texas (378)
United States (10766)
Utah (52)
Virginia (132)
Washington D.C. (41)
Washington State (180)
West Virginia (1)
Wisconsin (27)
271,779 Results for "lifeline pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
Big Pharma Provides Lifeline to Chinese Companies Struggling To Survive
Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is only scratching at the surface of partnership-ready biotechs in the region.
August 6, 2025
·
7 min read
·
Leslie Zhen Liang
Mergers & acquisitions
Sage’s Search for Lifeline Ran Into Defiant Biogen CEO
After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris Viehbacher spied a possible deal, but the smaller company wasn’t interested.
July 3, 2025
·
3 min read
·
Annalee Armstrong
Gene therapy
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in preclinical studies has shown the ability to cross the blood-brain barrier.
April 4, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Site Survival: Why Clinical Research Sites Need a Lifeline
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.
February 19, 2025
·
1 min read
·
Lori Ellis
Sponsored
Best Pharmaceutical Label Manufacturers: Reviews and Comparisons
Selecting the ideal pharmaceutical label manufacturer requires careful consideration. This article compares leading companies, highlighting their strengths in regulatory compliance, material performance, serialization, innovation, and sustainability, to help you make an informed decision for your product’s safety and success.
October 27, 2025
·
6 min read
Deals
Royalty Financing Serves as Lifeline for Some Biopharma Companies in Uncertain Market
As traditional fundraising methods falter for smaller firms, the rise of royalty deals is reshaping how companies access capital, offering an alternative that bypasses equity dilution and debt.
October 2, 2024
·
5 min read
·
Ben Hargreaves
Deals
Cash-Strapped Sangamo Gets Lifeline from Genentech in Potential $1.9B Neuro Deal
Sangamo Therapeutics announced Tuesday it secured an exclusive licensing agreement with Roche’s Genentech, which is paying $50 million in near-term upfront fees and milestone payments to develop novel genomic medicines for neurodegenerative diseases.
August 6, 2024
·
2 min read
·
Tyler Patchen
Press Releases
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer’s disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026
September 23, 2025
·
12 min read
Press Releases
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
October 3, 2025
·
5 min read
Press Releases
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
October 14, 2025
·
7 min read
1 of 27,178
Next
